Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $512.52, indicating a +0.06% shift from the previous trading day.

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed ...

Vertex Pharmaceuticals today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has granted consent for the expanded use of TRIKAFTA® ...

Recursion Pharmaceuticals appointed former FDA principal deputy commissioner Namandjé Bumpus, PhD, and Elaine Sun, the COO and CFO of Mammoth Biosciences, to its board of directors. CAMP4 Therapeutics ...

In March 2025, Vertex Pharmaceuticals Incorporated announced a study is to evaluate the safety, and tolerability and efficacy ...

The diabetes market is booming, with continuous glucose monitoring (CGM) and GLP-1 drugs leading the charge in innovation and ...

ASX gets smacked by Wall Street sell-off, MinRes tumbles after haul road drama, and all eyes now on the Fed's next move.

UnitedHealth Group's pharmacy benefit manager, Optum Rx, said on Wednesday it would ease requirements to get insurance ...

DelveInsight's "CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von ...

Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, and rising demand for targeted therapies in hematology ...